StuartRossSniderMD

Neurology • Tucson, AZ

Headache, Movement Disorder, Neurodegenerative, Clinical Pharmacology

Physician

Join to view full profile

Dr. Snider is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Snider's full profile

Already have an account?

Office
3191 W Windwalker Pl
Tucson, AZ 85742
Phone+1 406-475-1320
Is this information wrong?

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 1971 - 1973
Alameda Health System-Highland HospitalInternship, Transitional Year, 1966 - 1967
Northwestern University The Feinberg School of MedicineClass of 1966
University of Gothenburg with Arvid Carlsson, MD-PhDMD (post-doc), Neurosciences

Certifications & Licensure

AZ State Medical License 1982 - 2024
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

White Cotton Award for Best Research by an Intern Highland General Hospital, Oakland CA, 1968

Publications & Presentations

PubMed

Blood pressure control in stroke patients. What should the consulting neurologist advise?
Snider, S.R.> ;Neurology. 2003 Feb 11
201 citations
Controlled clinical trial of cannabidiol in Huntington's disease.
Paul Consroe, Joan Laguna, James Allender, Stuart R. Snider, Lawrence Z. Stern, Reuven Sandyk, Kurt Kennedy, Karl H. Schram> ;Pharmacology, Biochemistry, and Behavior. 1991 Nov 1
More on ciladopa.
Stuart R. Snider> ;Annals of Neurology. 1987 Oct 1
1 citations
Amantadine for Levodopa Resistant Parkinsonism
Reuven Sandyk, Robert P. Iacono, Stuart R. Snider> ;The International Journal of Neuroscience. 1987 Feb 1
98 citations
Open label evaluation of cannabidiol in dystonic movement disorders.
Paul Consroe, Reuven Sandyk, Stuart R. Snider> ;The International Journal of Neuroscience. 1986 Jan 1
Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease.
Sandyk R, Snider SR> ;Am J Psychiatry. 1986-01-01
5 citations
Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease
Todd C. Case, Stuart R. Snider, Victor J. Hruby, Todd W. Rockway> ;Life Sciences. 1985 Jul 1
9 citations
Octacosanol in parkinsonism.
Stuart R. Snider> ;Annals of Neurology. 1984 Dec 1
Pergolide treatment in parkinsonism.
Ilson J, Fahn S, Mayeux R, Cote LJ, Snider SR> ;Adv Neurol. 1983-01-01
44 citations
Cerebellar pathology in schizophrenia—Cause or consequence?
Stuart R. Snider> ;Neuroscience and Biobehavioral Reviews. 1982 Mar 1
Reversible focal hyperthermic effects on evoked auditory cerebral responses
Ray S. Snider, William J. Thomas, Stuart R. Snider> ;Experimental Neurology. 1982 Jan 1
Further experiences with low doses of bromocriptine in Parkinson's disease.
Fahn S, Côté LJ, Barrett RE, Snider SR> ;Adv. Biochem. Psychopharmacol.. 1980-01-01
275 citations
Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy
Ronald P. Lesser, Stanley Fahn, Stuart R. Snider, William P. Isgreen, > ;Neurology. 1979 Sep 1
46 citations
The role of bromocriptine in the treatment of parkinsonism
Stanley Fahn, Stuart R. Snider, William P. Isgreen, > ;Neurology. 1979 Aug 1
13 citations
Kainic acid: Enduring alterations in cerebellar morphology and in cerebral catecholamine and GABA concentrations after cerebellar injection in the rat
Stuart R. Snider, Ray S. Snider> ;Neuroscience Letters. 1979 May 1
Bromocriptine and dopamine receptor hypersensitivity.
Stuart R. Snider> ;Neurology. 1979 May 1
13 citations
Effect of a catechol-O-methyl transferase inhibitor, U-0521, with levodopa administration.
Stanley Fahn, Richard Comi, Stuart R. Snider, A.L.N. Prasad> ;Biochemical Pharmacology. 1979 Apr 1
10 citations
Interaction between bromocriptine and levodopa Biochemical basis for an improved treatment for parkinsonism
Cheryl S. Huit, Stuart R. Snider, Stanley Fahn> ;Neurology. 1977 Jun 1
6 citations
Changes in adrenal dopamine concentration after metyrapone or ACTH administration: implications for the in vivo regulation of dopamine beta-hydroxylase by glucocortico...
Stuart R. Snider, David I. Sahar, A.L.N. Prasad, Stanley Fahn> ;Life Sciences. 1977 Mar 15
17 citations
Is dopamine a neurohormone of the adrenal medulla? Studies with morphine stimulation.
Stuart R. Snider, Carl Miller, A.L.N. Prasad, V. Jackson, Stanley Fahn> ;Naunyn-Schmiedeberg's Archives of Pharmacology. 1977 Mar 1
Alterations in forebrain catecholamine metabolism produced by cerebellar lesions in the rat.
Snider SR, Snider RS> ;J. Neural Transm.. 1977-01-01
1 citations
Purkinje cell density effect on cerebellar stimulation.
Stuart R. Snider> ;Neurology. 1977 Jan 1
155 citations
Cerebellar pathways to ventral midbrain and nigra.
Ray S. Snider, A. Maiti, Stuart R. Snider> ;Experimental Neurology. 1976 Dec 1
46 citations
Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover.
Stuart R. Snider, Cheryl Hutt, Bruce Stein, A.L.N. Prasad, Stanley Fahn> ;The Journal of Pharmacy and Pharmacology. 2011 Apr 12
2 citations
Interpretation of regional changes in brain dopamine after stimulation
Stuart R. Snider> ;The Journal of Pharmacy and Pharmacology. 2011 Apr 12
Join now to see all